Evidence map›Paper›PMID 33218199›Full record

ArticleInternational journal of molecular sciences2020

Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7.

Jochen Rutz, Sarah Thaler, Sebastian Maxeiner, Felix K-H Chun, Roman A Blaheta

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jochen RutzDepartment of Urology, Goethe-University, 60323 Frankfurt am Main, Germany.
Sarah ThalerDepartment of Urology, Goethe-University, 60323 Frankfurt am Main, Germany.
Sebastian MaxeinerDepartment of Urology, Goethe-University, 60323 Frankfurt am Main, Germany.
Felix K-H ChunDepartment of Urology, Goethe-University, 60323 Frankfurt am Main, Germany.
Roman A BlahetaDepartment of Urology, Goethe-University, 60323 Frankfurt am Main, Germany.ORCID 0000-0002-0129-7972
Goethe University Frankfurt · DE

Funding

Brigitta & Norbert Muth Stiftung, Wiesbaden, Germany N/A
6 · The paper itself

Abstract

Prostate cancer patients whose tumors develop resistance to conventional treatment often turn to natural, plant-derived products, one of which is sulforaphane (SFN). This study was designed to determine whether anti-tumor properties of SFN, identified in other tumor entities, are also evident in cultivated DU145 and PC3 prostate cancer cells. The cells were incubated with SFN (1-20 µM) and tumor cell growth and proliferative activity were evaluated. Having found a considerable anti-growth, anti-proliferative, and anti-clonogenic influence of SFN on both prostate cancer cell lines, further investigation into possible mechanisms of action were performed by evaluating the cell cycle phases and cell-cycle-regulating proteins. SFN induced a cell cycle arrest at the S- and G2/M-phase in both DU145 and PC3 cells. Elevation of histone H3 and H4 acetylation was also evident in both cell lines following SFN exposure. However, alterations occurring in the Cdk-cyclin axis, modification of the p19 and p27 proteins and changes in CD44v4, v5, and v7 expression because of SFN exposure differed in the two cell lines. SFN, therefore, does exert anti-tumor properties on these two prostate cancer cell lines by histone acetylation and altering the intracellular signaling cascade, but not through the same molecular mechanisms.

Indexed as

AcetylationAnticarcinogenic AgentsCell Line, TumorCell ProliferationCyclin-Dependent KinasesCyclinsG2 Phase Cell Cycle CheckpointsHistonesHumansHyaluronan ReceptorsIsothiocyanatesMaleProstatic NeoplasmsProtein IsoformsSignal TransductionS PhaseAnticarcinogenic AgentsCD44 protein, humanCyclin-Dependent KinasesCyclinsHistonesHyaluronan ReceptorsIsothiocyanatesProtein IsoformssulforaphaneSulfoxidesCD44growthproliferationprostate cancersulforaphane

Identifiers

PMID33218199
PMCPMC7699211
OpenAlexW3099046961

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.